UA85198C2 - Производные морфолина как ингибиторы повторного поглощения норэпинефрина - Google Patents

Производные морфолина как ингибиторы повторного поглощения норэпинефрина

Info

Publication number
UA85198C2
UA85198C2 UAA200604519A UAA200604519A UA85198C2 UA 85198 C2 UA85198 C2 UA 85198C2 UA A200604519 A UAA200604519 A UA A200604519A UA A200604519 A UAA200604519 A UA A200604519A UA 85198 C2 UA85198 C2 UA 85198C2
Authority
UA
Ukraine
Prior art keywords
inhibitors
norepinephrine reuptake
morpholin
derivatives
morpholin derivatives
Prior art date
Application number
UAA200604519A
Other languages
English (en)
Ukrainian (uk)
Inventor
Гордон Айан Кэмпбелл
Мануэль Хавьер Кейзес-Томас
Тереза Ман
Джон Джозеф Мастерз
Хелена Катрин Эжени Рудик
Магнус Вильгельм Вальтер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85198(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA85198C2 publication Critical patent/UA85198C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Соединения общей формулы (І)(І)являются ингибиторами повторного поглощения норэпинефрина. Как таковые, они могут быть полезными для лечения расстройств центральной и/или периферической нервной системы.
UAA200604519A 2003-11-10 2004-10-28 Производные морфолина как ингибиторы повторного поглощения норэпинефрина UA85198C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0326148.4A GB0326148D0 (en) 2003-11-10 2003-11-10 Morpholine derivatives

Publications (1)

Publication Number Publication Date
UA85198C2 true UA85198C2 (ru) 2009-01-12

Family

ID=29726235

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200604519A UA85198C2 (ru) 2003-11-10 2004-10-28 Производные морфолина как ингибиторы повторного поглощения норэпинефрина

Country Status (34)

Country Link
US (1) US7423037B2 (ru)
EP (2) EP1682523B1 (ru)
JP (1) JP4850068B2 (ru)
KR (1) KR100783855B1 (ru)
CN (1) CN1878762B (ru)
AR (1) AR046927A1 (ru)
AT (1) ATE478057T1 (ru)
AU (1) AU2004289616B2 (ru)
BR (1) BRPI0415273B8 (ru)
CA (1) CA2544649C (ru)
CR (1) CR8390A (ru)
CY (1) CY1110796T1 (ru)
DE (1) DE602004028750D1 (ru)
DK (1) DK1682523T3 (ru)
EA (1) EA009960B1 (ru)
EC (1) ECSP066555A (ru)
ES (1) ES2348872T3 (ru)
GB (1) GB0326148D0 (ru)
HK (1) HK1095135A1 (ru)
HR (1) HRP20100476T1 (ru)
IL (1) IL175365A (ru)
MA (1) MA28330A1 (ru)
MY (1) MY141048A (ru)
NO (1) NO336268B1 (ru)
NZ (1) NZ546067A (ru)
PE (1) PE20050491A1 (ru)
PL (1) PL1682523T3 (ru)
PT (1) PT1682523E (ru)
SI (1) SI1682523T1 (ru)
SV (1) SV2006001934A (ru)
TW (1) TWI339658B (ru)
UA (1) UA85198C2 (ru)
WO (1) WO2005047272A1 (ru)
ZA (1) ZA200603680B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399557T1 (de) * 2003-12-12 2008-07-15 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
RU2613633C1 (ru) * 2016-03-09 2017-03-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Хлорид 4-[(1Е)-1-(6-хлор-4-оксо-4Н-хромен-3-ил)-4-метилпент-1-ен-3-ил]морфолин-4-ия, способ его получения и противотуберкулезная активность

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
NL108827C (ru) 1956-04-09
GB895309A (en) 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3141823A (en) 1962-09-04 1964-07-21 Res Lab Dr C Janssen N V Method for producing analgesia
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1999015177A1 (en) 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
NZ520349A (en) * 1998-01-21 2004-02-27 Glaxo Group Ltd (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2- morpholinol and its salts and pharmaceuticals thereof
AU5889100A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
DK1632234T3 (da) * 1999-07-01 2007-09-17 Pharmacia & Upjohn Co Llc (S,S)-reboxetin til behandling af kronisk træthedssyndrom
GB0120461D0 (en) * 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
JP2004277318A (ja) * 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
FR2852954B1 (fr) * 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PE20050491A1 (es) 2005-08-24
CY1110796T1 (el) 2015-06-10
CR8390A (es) 2007-12-07
HK1095135A1 (en) 2007-04-27
CN1878762B (zh) 2010-10-27
SV2006001934A (es) 2006-02-15
WO2005047272A1 (en) 2005-05-26
MY141048A (en) 2010-02-25
TW200524885A (en) 2005-08-01
EP1682523A1 (en) 2006-07-26
CN1878762A (zh) 2006-12-13
PT1682523E (pt) 2010-09-20
PL1682523T3 (pl) 2011-01-31
ZA200603680B (en) 2007-07-25
NO20062700L (no) 2006-08-08
US20070083046A1 (en) 2007-04-12
HRP20100476T1 (hr) 2010-10-31
DK1682523T3 (da) 2010-11-15
JP4850068B2 (ja) 2012-01-11
AR046927A1 (es) 2006-01-04
KR20060086408A (ko) 2006-07-31
JP2007510720A (ja) 2007-04-26
IL175365A (en) 2011-02-28
KR100783855B1 (ko) 2007-12-10
BRPI0415273B8 (pt) 2021-05-25
DE602004028750D1 (de) 2010-09-30
ECSP066555A (es) 2006-10-17
GB0326148D0 (en) 2003-12-17
US7423037B2 (en) 2008-09-09
TWI339658B (en) 2011-04-01
AU2004289616A1 (en) 2005-05-26
NZ546067A (en) 2009-04-30
AU2004289616B2 (en) 2010-08-05
EP2223916A1 (en) 2010-09-01
MA28330A1 (fr) 2006-12-01
IL175365A0 (en) 2006-09-05
BRPI0415273B1 (pt) 2019-04-30
BRPI0415273A (pt) 2006-12-19
EA200600945A1 (ru) 2006-10-27
EP1682523B1 (en) 2010-08-18
EA009960B1 (ru) 2008-04-28
CA2544649A1 (en) 2005-05-26
CA2544649C (en) 2012-08-14
SI1682523T1 (sl) 2010-12-31
ES2348872T3 (es) 2010-12-16
ATE478057T1 (de) 2010-09-15
NO336268B1 (no) 2015-07-06

Similar Documents

Publication Publication Date Title
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
MX2007007919A (es) Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
TW200510301A (en) Novel compounds
IL174210A0 (en) 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
TW200510303A (en) Novel compounds
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
SI1506185T1 (sl) Spojine in njihova uporaba kot inhibitorji 5-HT
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2006037032A3 (en) Prodrugs of protein tyrosine kinase inhibitors
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
WO2004052858A3 (en) Inhibitors of monoamine uptake
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
UA94054C2 (en) Nitrocatechol derivatives as comt inhibitors
WO2006133339A3 (en) Monoamine re-uptake inhibitors and methods relating thereto
NO20062700L (no) Morfolinderivater som norepinefrin reopptaksinhibitorer